

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
30 April 2020 (30.04.2020)



(10) International Publication Number  
**WO 2020/084496 A1**

(51) International Patent Classification:

A61K 38/18 (2006.01) C07K 14/575 (2006.01)  
A61K 38/22 (2006.01) C07K 14/765 (2006.01)  
A61K 47/64 (2017.01) C12N 15/11 (2006.01)  
C07K 14/495 (2006.01) C12N 15/63 (2006.01)

(21) International Application Number:

PCT/IB2019/059029

(22) International Filing Date:

22 October 2019 (22.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/748,603 22 October 2018 (22.10.2018) US

(71) Applicant: JANSSEN PHARMACEUTICA NV  
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant (for US only): MULLICAN, Shannon  
[US/US]; 1400 McKean Road, Spring House, Pennsylvania  
19477 (US).

(72) Inventors: RANKIN, Matthew M.; 1400 McKean Road,  
Spring House, Pennsylvania 19477 (US). LIN-SCHMIDT,  
Xiefan; 1400 McKean Road, Spring House, Pennsylvania  
19477 (US). HUANG, Chichi; 1400 McKean Road, Spring  
House, Pennsylvania 19477 (US). FURMAN, Jennifer;  
3210 Merryfield Row, San Diego, California 92121 (US).  
ZHENG, Songmao; 1400 McKean Road, Spring House,  
Pennsylvania 19477 (US). RINGWALA, Shamina; 1400

McKean Road, Spring House, Pennsylvania 19477 (US).  
NELSON, Serena M.; 3210 Merryfield Row, San Diego,  
California 92121 (US).

(74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON &  
JOHNSON, One Johnson & Johnson Plaza, New  
Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(54) Title: GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS  
AND USES THEREOF




FIG. 1

(57) Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

[Continued on next page]

WO 2020/084496 A1

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*